There is little information on the effectiveness of the pneumococcal vaccines (PVs), especially for the pneumococcal conjugate vaccines (PCVs), in HIV-infected patients in the modern antiretroviral era. This is a case–control study where cases were people living with HIV (PLWH) with confirmed pneumococcal infection (CPI) and controls were PLWH without CPI matched with cases by gender and year of HIV diagnosis. The selection process was blinded to the study factor (vaccination). Sample size estimation yielded 61 cases and 183 controls. We analyzed the effect of PV on CPI using Cox proportional-hazards regression model with time-dependent covariates. We included 256 subjects: 64 cases, and 192 controls. PVs had been administered to 115 (45%) patients. Only the modified Charlson Comorbidity Index (HR 1.16, 95%CI 1.06–1.27, P = 0.001) and the CD4 nadir (HR 0.99, 95% CI 0.98–0.99, P = 0.001) were independently associated with CPI. Receipt of PV was not associated with CPI after adjusting in the multivariate model with time protection as a dependent covariate (HR 0.65, 95% CI 0.35–1.32 P = 0.250). We also investigated the influence of different immunization schedules. In an adjusted model, we found no evidence of protection against CPI, including double immunization schedules (HR 0.42 95%CI 0.15–1.19 P = 0.102). In this case–control study, we could not show an association between pneumococcal vaccination and confirmed pneumococcal infection, although a protective effect of particular schedules of immunization cannot be ruled out.
JanoffENBreimanRFDaleyCL, et al.
Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med1992;
117: 314–324.
2.
NuortiJPButlerJCGellingL, et al.
Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med2000;
132: 182–190.
3.
HeffernanRTBarrettNLGallagherKM, et al.
Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J Infect Dis2005;
191: 2038–2045.
4.
SogaardOSLohseNGerstoftJ, et al.
Hospitalization for pneumonia among individuals with and without HIV infection, 1995–2007: a Danish population based, nationwide cohort study. Clin Infect Dis2008;
47: 1345–1353.
5.
HartMSteelAClarkSA, et al.
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol2007;
178: 8212–8220.
6.
PedersenRHLohseNØstergaardL, et al.
The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med2011;
12: 323–333.
7.
MunierA-Lde LastoursVPorcherR, et al.
Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era. Int J STD Aids2014;
25: 1022–1028. .
8.
HarboeZBLarsenMVLadelundS, et al.
Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV infected injecting drug users. Clin Infect Dis2014;
59: 1168–1176.
9.
Kaplan JE, Masur H, Holmes KK (2002) Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports. 51-RR-8, pp.1–52. ISSN 1057-5987.
10.
DworkinMSWardJWHansonDL, et al.
Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis2001;
32: 794–800.
11.
ThornhillJSivaramakrishnanAOrkinC.Pneumococcal vaccination in people living with HIV. Vaccine2015;
33: 3159–3160.
12.
FrenchNNakiyingiJCarpenterLM, et al.
23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet2000;
355: 2106–2111.
13.
WateraCNakiyingiJMiiroG, et al.
23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS2004;
18: 210–1213.
14.
FrenchNGordonSBMwalukomoT, et al.
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med2010;
362: 812–822.
15.
GerettiAMBrookGCameronC, et al.
British HIV association guidelines on the use of vaccines in HIV-positive adults 2015. HIV Med2016;
17: s2–81.
16.
González-RomoFPicazoJJ, GRojasALabrador HorrilloM, et al.
Consenso sobre la vacunación anti-neumocócica en el adulto por riesgo de edad y patología de base. Actualización 2017. Rev Esp Quim2017;
30: 142–168.
17.
European AIDS Clinical Society. European AIDS clinical society (EACS) guidelines. Version 9. Brussels, Belgium: Author, 2017, p.72.
18.
Centers for Disease Control and Prevention, & Centers for Disease Control and Prevention. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. MMWR 2019; 58(RR-11): 1–167.
19.
FeikinDRFeldmanCSchuchatA, et al.
Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis2004;
4: 445–455.
20.
Insight Start Study GroupInitiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med2015;
373: 795–807.
21.
JordanoQFalcoVAlmiranteB, et al.
Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis2004;
38: 1623–1628.
22.
LesourdALeporrierJDelbosV, et al.
Antiretroviral therapy as prevention of … pneumococcal infections?Open Forum Infect Dis2016;
3: ofw228.
23.
CillónizCTorresAManzardoC, et al.
Community-acquired pneumococcal pneumonia in virologically suppressed HIV-infected adult patients: a matched case–control study. Chest2017;
152: 295–303.
24.
GrauIArdanuyCLiñaresJ, et al.
Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med2009;
10: 488–495.
25.
KaplanJEBensonCHolmesKK, et al.
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America depart. Centers Dis Control Prevent2009;
58: 1–209.
26.
MillerEAndrewsNJWaightPA, et al.
Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine2011;
29: 9127–9131.
27.
LuCLChangSYChuangYC, et al.
Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide. Vaccine2014;
32: 1031–1035.
28.
LeeKYTsaiMSKuoKC, et al.
Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy. Hum Vaccines Immunother2014;
10: 3700–3710.
29.
RozenbaumMHVan HoekAJFlemingD, et al.
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ2012;
345: 1–17.
30.
Center Disease Control P.
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep2012;
61: 816–819.
31.
KroonFPDisselJTVan RavensbergenE, et al.
Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine2000;
19: 886–894.
32.
MiiroGKayhtyHWateraC, et al.
Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis2005;
192: 1801–1805.
